Cancer Translational Medicine

MINI REVIEW
Year
: 2020  |  Volume : 6  |  Issue : 1  |  Page : 17--20

Potential inhibitor for 2019-novel coronaviruses in drug development


Xiaohui Xu1, Zilong Dang2, Lei Zhang3, Lingxue Zhuang4, Wutang Jing5, Lupeng Ji6, Guoyu Qiu1 
1 Department of Chemical Drug, Lanzhou Institutes for Food and Drug Control, Lanzhou, Gansu, China
2 Department of Pharmacy, First Hospital of Lanzhou University, Lanzhou, Gansu, China
3 Department of Biliary-Pancreatic Surgery, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
4 Department of Pneumology, First Lanzhou People's Hospital, Lanzhou, Gansu, China
5 Department of Surgery, Gansu People's Hospital, Lanzhou, Gansu, China
6 Department of Medicine, The Fifth People's Hospital of Zhuhai, Zhuhai, Guangdong, China

Correspondence Address:
Prof. Guoyu Qiu
Department of Chemical Drug, Lanzhou Institutes for Food and Drug Control, No. 988, Peng Jia Ping Town, Lanzhou 730050, Gansu
China

The coronavirus disease 2019 (COVID-19), which is first detected in Wuhan, China, is a virus identified as the cause of pneumonia. In the event of epidemic outbreak, a series of actions have been taken by the Chinese government to control the pandemic of the virus, and effective medical methods are in urgent need to prevent COVID-19 infection and cure the disease, especially a drug that can suppress COVID-19 is urgently needed. However, there are no specific drugs and vaccine that can prevent coronavirus infection. Some research works on the transmissibility, severity, and other features associated with this virus are ongoing. Some works about new drug against COVID-19 are carried out; more time is required to develop an effective drug against pneumonia caused by COVID-19. Now, to develop broad-spectrum antiviral agents, there is a quick method to identify drugs with high binding capacity with COVID-19 by virtual screening based on the clinical drug libraries; all these drugs have been widely used in clinical applications with guaranteed safety, which may serve as promising candidates to treat the infection of COVID-19. In this article, we summarize the discovery and clinical application of specific drugs against COVID-19 as potential inhibitors to alleviate the current epidemic.


How to cite this article:
Xu X, Dang Z, Zhang L, Zhuang L, Jing W, Ji L, Qiu G. Potential inhibitor for 2019-novel coronaviruses in drug development.Cancer Transl Med 2020;6:17-20


How to cite this URL:
Xu X, Dang Z, Zhang L, Zhuang L, Jing W, Ji L, Qiu G. Potential inhibitor for 2019-novel coronaviruses in drug development. Cancer Transl Med [serial online] 2020 [cited 2020 Aug 13 ];6:17-20
Available from: http://www.cancertm.com/article.asp?issn=2395-3977;year=2020;volume=6;issue=1;spage=17;epage=20;aulast=Xu;type=0